Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $500,100.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Halozyme Therapeutics Trading Up 5.0 %

NASDAQ HALO opened at $53.76 on Thursday. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a market cap of $6.84 billion, a P/E ratio of 17.80, a P/E/G ratio of 0.44 and a beta of 1.24. The stock’s 50-day moving average is $50.10 and its 200-day moving average is $54.00.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $68.00 price target on shares of Halozyme Therapeutics in a research report on Monday, December 30th. Piper Sandler raised their price objective on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. JMP Securities upped their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.11.

Institutional Trading of Halozyme Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Halozyme Therapeutics during the second quarter worth $49,000. GAMMA Investing LLC increased its holdings in Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares in the last quarter. Toth Financial Advisory Corp acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $57,000. FSC Wealth Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the third quarter valued at about $65,000. Finally, Park Place Capital Corp boosted its position in shares of Halozyme Therapeutics by 828.1% during the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 1,209 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.